Literature DB >> 11553568

Regulatory effects of macrophage inflammatory protein 1alpha/CCL3 on the development of immunity to Cryptococcus neoformans depend on expression of early inflammatory cytokines.

M A Olszewski1, G B Huffnagle, T R Traynor, R A McDonald, D N Cook, G B Toews.   

Abstract

Macrophage inflammatory protein 1alpha (MIP-1alpha)/CCL3 prevents the development of eosinophilic pneumonia (EP) driven by a nonprotective T2-type immunity during infection with a highly virulent strain of Cryptococcus neoformans. The present study evaluated the interaction of MIP-1alpha with other innate immune system cytokines by comparing the immune responses that followed pulmonary infections with high- (C. neoformans 145A) and low (C. neoformans 52D)-virulence strains. In contrast to what was found for C. neoformans 145A infection, lack of MIP-1alpha in C. neoformans 52D infection did not cause the development of EP. C. neoformans 52D induced tumor necrosis factor alpha (TNF-alpha), gamma interferon (IFN-gamma), and MCP-1 in the lungs of infected wild-type (WT) and MIP-1alpha knockout (KO) mice by day 7 postinfection. Both WT and MIP-1alpha KO mice subsequently cleared this infection. Thus, the robust expression of early inflammatory cytokines in C. neoformans 52D-infected mice promoted the development of protective immunity even in the absence of MIP-1alpha. Alternatively, C. neoformans 145A-infected WT and MIP-1alpha KO mice had diminished TNF-alpha, IFN-gamma, and macrophage chemoattractant protein 1 (MCP-1) responses, indicating that virulent C. neoformans 145A evaded early innate host defenses. However C. neoformans 145A-infected WT mice had an early induction of MIP-1alpha and subsequently did not develop EP. In contrast, C. neoformans 145A-infected MIP-1alpha KO mice developed EP and had increased C. neoformans dissemination into the brain by day 35. We conclude that, in the absence of other innate immune response effector molecules, MIP-1alpha is crucial to prevent the development of EP and to control C. neoformans dissemination to the brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553568      PMCID: PMC98759          DOI: 10.1128/IAI.69.10.6256-6263.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

Review 1.  Chemokines: a new classification system and their role in immunity.

Authors:  A Zlotnik; O Yoshie
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

2.  CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection.

Authors:  T R Traynor; W A Kuziel; G B Toews; G B Huffnagle
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

3.  T helper 1 and T helper 2 cells respond differentially to chemokines.

Authors:  J T Siveke; A Hamann
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

4.  Capsule size of Cryptococcus neoformans: control and relationship to virulence.

Authors:  M A Dykstra; L Friedman; J W Murphy
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

5.  Chemokine responses and accumulation of inflammatory cells in the lungs of mice infected with highly virulent Cryptococcus neoformans: effects of interleukin-12.

Authors:  K Kawakami; K Shibuya; M H Qureshi; T Zhang; Y Koguchi; M Tohyama; Q Xie; S Naoe; A Saito
Journal:  FEMS Immunol Med Microbiol       Date:  1999-09

6.  Differential effect of Cryptococcus neoformans on the production of IL-12p40 and IL-10 by murine macrophages stimulated with lipopolysaccharide and gamma interferon.

Authors:  K Kawakami; M H Qureshi; Y Koguchi; K Nakajima; A Saito
Journal:  FEMS Microbiol Lett       Date:  1999-06-01       Impact factor: 2.742

7.  Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans.

Authors:  G B Huffnagle; L K McNeil; R A McDonald; J W Murphy; G B Toews; N Maeda; W A Kuziel
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

8.  The role of macrophage inflammatory protein-1 alpha/CCL3 in regulation of T cell-mediated immunity to Cryptococcus neoformans infection.

Authors:  M A Olszewski; G B Huffnagle; R A McDonald; D M Lindell; B B Moore; D N Cook; G B Toews
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

9.  Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents.

Authors:  D L Goldman; B C Fries; S P Franzot; L Montella; A Casadevall
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

10.  T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice.

Authors:  G B Huffnagle; J L Yates; M F Lipscomb
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

View more
  31 in total

1.  Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection.

Authors:  Amy C Herring; John Lee; Roderick A McDonald; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  The role of MIP-1alpha in experimental hypersensitivity pneumonitis.

Authors:  M Schuyler; K Gott; V French
Journal:  Lung       Date:  2004       Impact factor: 2.584

3.  Transient neutralization of tumor necrosis factor alpha can produce a chronic fungal infection in an immunocompetent host: potential role of immature dendritic cells.

Authors:  Amy C Herring; Nicole R Falkowski; Gwo-Hsiao Chen; Rod A McDonald; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Effect of a CD4-depleting antibody on the development of Cryptococcus neoformans-induced allergic bronchopulmonary mycosis in mice.

Authors:  Shikha Arora; Roderick A McDonald; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

5.  Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99.

Authors:  Yanmei Zhang; Fuyuan Wang; Kristin C Tompkins; Andrew McNamara; Aditya V Jain; Bethany B Moore; Galen B Toews; Gary B Huffnagle; Michal A Olszewski
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

6.  Early induction of CCL7 downstream of TLR9 signaling promotes the development of robust immunity to cryptococcal infection.

Authors:  Yafeng Qiu; Stuart Zeltzer; Yanmei Zhang; Fuyuan Wang; Gwo-Hsiao Chen; Jeremy Dayrit; Benjamin J Murdock; Urvashi Bhan; Galen B Toews; John J Osterholzer; Theodore J Standiford; Michal A Olszewski
Journal:  J Immunol       Date:  2012-03-14       Impact factor: 5.422

7.  CCR2 mediates conventional dendritic cell recruitment and the formation of bronchovascular mononuclear cell infiltrates in the lungs of mice infected with Cryptococcus neoformans.

Authors:  John J Osterholzer; Jeffrey L Curtis; Timothy Polak; Theresa Ames; Gwo-Hsiao Chen; Rod McDonald; Gary B Huffnagle; Galen B Toews
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

8.  Involvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo.

Authors:  Lauren E Yauch; Michael K Mansour; Shmuel Shoham; James B Rottman; Stuart M Levitz
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

9.  Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung.

Authors:  John J Osterholzer; Rishi Surana; Jami E Milam; Gerald T Montano; Gwo-Hsiao Chen; Joanne Sonstein; Jeffrey L Curtis; Gary B Huffnagle; Galen B Toews; Michal A Olszewski
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

10.  Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion.

Authors:  Michal A Olszewski; Mairi C Noverr; Gwo-Hsiao Chen; Galen B Toews; Gary M Cox; John R Perfect; Gary B Huffnagle
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.